Articles

For patients with myelofibrosis, fedratinib has emerged as another option for first-line therapy after prior ruxolitinib therapy. In a real-world setting, data indicate earlier initiation of fedratinib may be of clinical benefit in this patient population. Read More ›

Patients with a low platelet count represent a difficult-to-treat group because ruxolitinib treatment is typically first-line therapy for myelofibrosis and is associated with suboptimal or loss of response and thrombocytopenia. Parsaclisib may be an effective add-on option for this patient subgroup. Read More ›

FREEDOM2 is the first trial to compare fedratinib to best available therapies, including ruxolitinib and other JAK inhibitors, in patients with myelofibrosis who were previously treated with ruxolitinib for at least 3 months. Read More ›

The rate of thrombus formation in patients with myelofibrosis is not well-defined. The intersection of IPSS score and JAK mutation may reliably indicate risk of vascular events in these patients. Read More ›

Patients with advanced myelofibrosis and heavy mutation burden have limited safe and effective therapeutic options. Preliminary clinical trial evidence indicates bomedemstat provides clinical benefit to patients in this population. Read More ›

Evidence suggests fedratinib, a selective JAK2 inhibitor, demonstrates safety and efficacy in patients with myelofibrosis previously treated with ruxolitinib with appropriate mitigation strategies. Read More ›

Myelofibrosis is associated with poor overall survival and clinical outcomes. Treatment with ruxolitinib earlier in disease course shows promise for improving symptoms and overall survival. Read More ›

Criteria to assess presenting patterns of organ damage have not been extensively evaluated. Preliminary evidence suggests identifying these patterns could be useful in profiling organ dysfunction in avapritinib clinical trials. Read More ›

Gilteritinib plus azacitidine led to significantly higher composite complete remission rates but did not provide a survival advantage compared with azacitidine alone in patients with newly diagnosed FLT3^mut+ AML ineligible for intensive induction chemotherapy. Read More ›

MRD status at the time of allogeneic stem-cell transplantation and the number of remissions prior to transplant were shown to be important independent prognostic factors in patients with AML. Read More ›